Interpreting results of prostate-specific antigen testing for early detection of prostate cancer

Journal of General Internal Medicine

Volumn 11, Issue 9, 1996, Pages 505-512

  Meigs, James B ^c   Barry, Michael J ^d   Oesterling, Joseph E ^a   Jacobsen, Steven J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MAYO CLINIC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE

Author keywords

diagnosis; likelihood ratio; prostate specific antigen; prostatic hypertrophy; prostatic neoplasms

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PROSTATE CANCER; PROSTATE HYPERTROPHY; SCREENING TEST; STATISTICAL MODEL;

EID: 0029836946     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02599596     Document Type: Article

References (27)

1. Potosky AL, Miller BA, Albertson PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-52.
2. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate specific antigen testing. JAMA. 1995;274:1445-9.
3. Meigs JB, Barry MJ, Rimm EB, Giovannucci E, Stampfer MJ, Kawachi I. Are the wrong men receiving PSA testing for early detection of prostate cancer? The Health Professionals Follow-up Study. J Gen Intern Med. 1996;11(suppl):127. Abstract.
4. Sershon PD, Barry MJ, Oesterling JE. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol. 1994;25:281-7.
5. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-58.
6. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-90.
7. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-16.
8. Oesterling JE. Prostate specific antigen. A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23.
9. Gillatt D, Reynard JM. What is the normal 'range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. Br J Urol. 1995;75:341-6.
10. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-94.
11. Oesterling JK, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270: 860-4.
12. Meigs JB, Barry MJ. The natural history of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. eds. Textbook of Benign Prostatic Hyperplasia. Oxford, UK: Isis Medical Media, Ltd: 1996:125-35.
13. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-91.
14. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22:31-7.
15. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, Mass: Little, Brown and Co; 1991.
16. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763-70.
17. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? A four part policy analysis, part I: framing the debate. Urology. 1995;46:2-13.
18. Simel DL, Samsa GP, Matchar DB. Likelihood ratios for continuous test results - making the clinicians' job easier or harder? J Clin Epidemiol. 1993;46:85-93.
19. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-9.
20. Barry M, Fowler F, O'Leary M, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148:1549-57.
21. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61.
22. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, Md: William and Wilkins; 1996.
23. American Urological Association. American Urological Association Executive Committee Report, 1992. Baltimore, Md: American Urological Association; 1992.
24. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA. 1993;43:42-7.
25. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-20.
26. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology. 1993;42:390-7.
27. Barry MJ, Girman CJ, O'Leary MP, et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. J Urol. 1995;153:99-103.